AVEO Pharmaceuticals joins Russell 2000 Index and S&P MidCap 400

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Jun 29 2010AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company has been added to the Russell 2000® Index, as part of the annual reconstitution of the entire Russell family of indexes that took place on June 25, 2010 following the close of the market. The Russell 2000® Index, a subset of the Russell 3000® Index, measures the performance of the small-cap segment of U.S. equities.

In addition, AVEO was added to the S&P MidCap 400 on June 18, 2010 as part of the quarterly share rebalance of S&P Total Market Index. The S&P MidCap 400 measures the performance of the mid-cap segment of U.S. equities.

Source:

AVEO Pharmaceuticals

Posted in:

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Study finds major gaps in cancer screening use in Federally Qualified Health Centers
Cancer history raises cardiovascular disease risk in hypertensive patients
Aspirin shows no benefit in preventing breast cancer recurrence, study finds
Exposed to agent orange at US bases, veterans face cancer without VA compensation
Loneliness increases mortality risk in cancer survivors, study finds
First FDA-approved cellular therapy for metastatic melanoma available in South Florida
Gut microbiome study challenges established cancer biomarkers, identifies new bacterial links to colorectal cancer
New blood test shows promise in early detection of ovarian cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer